High Health-Care Utilization (HCU) and Costs Associated with Diabetes Mellitus (DM) and Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) in Medicare Patients

被引：0
|
作者：
Gordon, Stuart
Fraysse, Jeremy
Li, Suying
Ozbay, A. Burak
Wong, Robert
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-1253-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1253-P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
    Wen, Xuerong
    Wang, Shuang
    Taveira, Tracey H.
    Akhlaghi, Fatemeh
    PLOS ONE, 2021, 16 (09):
  • [32] Role of Genetic Polymorphisms in the Development of Nonalcoholic Fatty Liver Disease (NAFLD) and Steatohepatitis (NASH)
    Bril, Fernando
    Kawaguchi-Suzuki, Marina
    Frye, Reginald
    Sanchez, Paola Portillo
    Maximos, Maryann
    Lai, Song
    Hardies, Jean
    Tio, Fermin
    Cusi, Kenneth
    HEPATOLOGY, 2014, 60 : 585A - 585A
  • [33] The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Among Patients with Psoriasis and Psoriatic Arthritis in a Tertiary Care Dermatology and Rheumatology Clinic
    Fewell, Allyson
    Lamb, Paul B.
    Roberts, Katharine K.
    Battafarano, Daniel
    Owens, Nicole M.
    Harrison, Stephen A.
    HEPATOLOGY, 2012, 56 : 897A - 897A
  • [34] MODELING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NONALCOHOLIC STEATOHEPATITIS (NASH) WITH HUMAN MULTI-CELL-LINEAGE LIVER ORGANOIDS
    Zhang, Wenjun
    Park, Yujin
    Thadasina, Deepthi
    Isidan, Abdulkadir
    Bolujo, Ifeoluwa
    Wilmes, Danielle M.
    Farag, Kristine
    Lopez, Kevin
    Cross-Najafi, Arthur A.
    Li, Ping
    Kyritsi, Konstantina
    Kennedy, Lindsey
    Glaser, Shannon S.
    Francis, Heather L.
    Alpini, Gianfranco
    Ekser, Burcin
    HEPATOLOGY, 2022, 76 : S699 - S700
  • [35] Increased Risk of Mortality in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) Patients: Real-World Analysis of 2007-2015 Medicare Data
    Loomba, Rohit
    Fraysse, Jeremy
    Li, Suying
    Harrison, Stephen A.
    HEPATOLOGY, 2018, 68 : 1294A - 1294A
  • [36] Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development
    Alkhouri, Naim
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (02) : 115 - 116
  • [37] EMPHASIZING DIVERSITY IN NONALCOHOLIC STEATOHEPATITIS (NASH) STUDIES: CHARACTERIZATION OF A NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) SCREENING DATABASE.
    Paglialunga, S.
    Jaycox, S.
    Kar, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S39 - S39
  • [38] Effect of Metformin on Ballooning Degeneration in Nonalcoholic Steatohepatitis (NASH): When to Use Metformin in Nonalcoholic Fatty Liver Disease (NAFLD)
    Doycheva, Iliana
    Loomba, Rohit
    ADVANCES IN THERAPY, 2014, 31 (01) : 30 - 43
  • [39] Effect of Metformin on Ballooning Degeneration in Nonalcoholic Steatohepatitis (NASH): When to Use Metformin in Nonalcoholic Fatty Liver Disease (NAFLD)
    Iliana Doycheva
    Rohit Loomba
    Advances in Therapy, 2014, 31 : 30 - 43
  • [40] Clinical Utility of a Noninvasive Metabolic Approach in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in Type 2 Diabetes
    Bellido, Virginia
    Martinez-Arranz, Ibon
    Goicolea, Ignacio
    Amor, Antonio J.
    Pi, Javier
    Perez, Antonio
    Espiga, Javier
    Montalban, Coral
    Mayo, Rebeca
    Gaztambide, Sonia
    DIABETES, 2020, 69
12345